StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Other Rare Disease medicines by Year

Other Rare Disease medicines — Worldwide product sales ($M) ($M)

AstraZeneca Other Rare Disease medicines: $231M in FY2025.

Latest, FY2025
231
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 6-K FY2025Q4 Earnings Release

Where the FY2025 figure comes from

“|| Other Rare Disease | 231 | 11 | 10 | 113 | 14 | 40 | 16 | 18 | 67 | 1 | (2) | 11 | 23 | 23”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Rare Disease medicines — Worldwide product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025231–Form 6-K FY2025Q4 Earnings Release ↗

Breakdown

What makes up other Rare Disease medicines

Cite this data

StockData. (2026). AstraZeneca Other Rare Disease medicines ($M), annual FY2025–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-other-rare-world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.